Compare Jabil Inc (JBL) vs Eli Lilly And Co (LLY) Price & Performance

JBL trades at $299.47, down 3.14% today amid a bearish technical signal, though recent Q4 2026 earnings beat expectations with EPS of $4.40 versus $4.07 expected. The company shows strong fundamentals with revenue growth to $29.80B in 2025 and projected 24% growth in fiscal 2027 driven by AI infrastructure demand. Analyst consensus remains bullish with a $434.75 price target, representing 45% upside potential from current levels.

The stock presents a compelling growth opportunity with robust AI-driven expansion and strong institutional support, though technical weakness and market volatility pose near-term risks. With zero sell ratings and 61% buy recommendations, Wall Street sees significant upside despite recent price pressure from broader market sentiment.

Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.

Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.